Baseline characteristics of patients who underwent CART therapy for THRLBCL reported to the CIBMTR between June 2015 and March 2022 (N=58)
| Characteristic . | n (%) . |
|---|---|
| Age at CART infusion, y, median (range) | 49 (19-76) |
| Female sex | 12 (21) |
| Race | |
| White | 40 (69) |
| Black/African American | 11 (19) |
| Other/not reported | 7 (13) |
| Ethnicity | |
| Non-Hispanic/Non-Latino | 51 (88) |
| Hispanic/Latino | 3 (5) |
| Other/not reported | 4 (7) |
| Preinfusion Karnofsky performance status | |
| 90-100 | 28 (48) |
| 70-80 | 22 (38) |
| <60 | 2 (3) |
| Not reported | 6 (10) |
| HCT-CI | |
| 0 | 17 (29) |
| 1-2 | 19 (32) |
| 3+ | 19 (33) |
| Not reported | 3 (5) |
| Bulky disease before CART infusion | |
| 0-5 cm | 19 (33) |
| 5-10 cm | 13 (22) |
| >10 cm | 4 (7) |
| Not reported | 22 (38) |
| Bone marrow involvement at diagnosis | 12 (21) |
| Received bridging therapy | |
| No | 32 (55) |
| Yes | 18 (31) |
| Not reported | 8 (14) |
| Lines of prior therapy, median (range) | 3 (1-7) |
| Prior autologous transplant | 21 (36) |
| Prior allogeneic transplant | 1 (2) |
| Product | |
| Axi-cel | 40 (69) |
| Tisa-cel | 15 (26) |
| Liso-cel | 3 (5) |
| Characteristic . | n (%) . |
|---|---|
| Age at CART infusion, y, median (range) | 49 (19-76) |
| Female sex | 12 (21) |
| Race | |
| White | 40 (69) |
| Black/African American | 11 (19) |
| Other/not reported | 7 (13) |
| Ethnicity | |
| Non-Hispanic/Non-Latino | 51 (88) |
| Hispanic/Latino | 3 (5) |
| Other/not reported | 4 (7) |
| Preinfusion Karnofsky performance status | |
| 90-100 | 28 (48) |
| 70-80 | 22 (38) |
| <60 | 2 (3) |
| Not reported | 6 (10) |
| HCT-CI | |
| 0 | 17 (29) |
| 1-2 | 19 (32) |
| 3+ | 19 (33) |
| Not reported | 3 (5) |
| Bulky disease before CART infusion | |
| 0-5 cm | 19 (33) |
| 5-10 cm | 13 (22) |
| >10 cm | 4 (7) |
| Not reported | 22 (38) |
| Bone marrow involvement at diagnosis | 12 (21) |
| Received bridging therapy | |
| No | 32 (55) |
| Yes | 18 (31) |
| Not reported | 8 (14) |
| Lines of prior therapy, median (range) | 3 (1-7) |
| Prior autologous transplant | 21 (36) |
| Prior allogeneic transplant | 1 (2) |
| Product | |
| Axi-cel | 40 (69) |
| Tisa-cel | 15 (26) |
| Liso-cel | 3 (5) |
Data are presented for 58 patients.
HCT-CI, hematopoietic cell transplantation–comorbidity index.